Re: pCR rates for herceptin based neoadjuvant therapy approach 65%!!!
Lani as I am part of the 35% for which Herceptin did not seem to work during neoadjuvant treatment, I would like to know if in the study they have a more detailed analysis of the subtypes (ER and PR for example).
(I first had 3 Fecs which reduced the tumor 60%, checked with MRI, then 12 weeks of Taxol herceptin with no additional results. After surgery my tumor was still almost 2cm and I had 3 positive nodes. My onc had me finish my year of herceptine and starded me on arimidex and then I was lucky he could put me on Tykerb for an extra year. I am just hoping Tykerb did the job Herceptin did not do).
Michka
__________________
08.2006 3 cm IDC Stage 2-3, HER2 3+ ER+90% PR 20%
FEC, Taxol+ Herceptin, Mastectomy, Radiation, Herceptin 1 year followed by Tykerb 1 year,Aromasin /Faslodex
12.2010 Mets to liver,Herceptin+Tykerb
03.2011 Liver resection ER+70% PR-
04.2011 Herceptin+Navelbine+750mg Tykerb
06.2011 Liver ned, Met to sternum. Added Zometa 09.2011 Cyberknife for sternum
11.2011 Pet clear. Stop Navelbine, continuing on Hercpetin+Tykerb+Aromasin
02.2012 Mets to lungs, nodes, liver
04.2012 TDM1, Ned in 07.2012
04.2015 Stop TDM1/Kadcyla, still Ned, liver problems
04.2016 Liver mets. Back on Kadcyla
08.2016 Kadcyla stopped working. mets to liver lungs bones
09.2016 Biopsy to liver. no more HER2, still ER+
09.2016 CMF Afinitor/Aromasin/ Xgeva.Met to eye muscle Cyberknife
01.2017 Gemzar/Carboplatin/ Ibrance/Faslodex then Taxotere
02.2017 30 micro mets to brain breathing getting worse and worse
04.2017 Liquid biopsy/CTC indicates HER2 again. Start Herceptin with Halaven
06.2017 all tumors shrunk 60% . more micro mets to brain (1mm mets) no symptoms
|